Format

Send to

Choose Destination
Expert Opin Biol Ther. 2015;15(11):1647-51. doi: 10.1517/14712598.2015.1092518. Epub 2015 Sep 28.

Middle East respiratory syndrome: current status and future prospects for vaccine development.

Author information

1
a 1 Lindsley F. Kimball Research Institute, New York Blood Center , NY, USA +1 212 570 3459 ; ldu@nybloodcenter.org.
2
b 2 Fudan University, Shanghai Medical College and Institute of Medical Microbiology, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health , Shanghai, China +1 212 570 3058 ; sjiang@nybloodcenter.org.

Abstract

The outbreaks of Middle East respiratory syndrome (MERS) previously in Middle East and recently in South Korea have raised serious concerns worldwide, reinforcing the importance of developing effective and safe vaccines against MERS-coronavirus (MERS-CoV). A number of vaccine candidates have been developed on the basis of viral vectors, recombinant proteins, DNAs, nanoparticles, and recombinant MERS-CoV, and some of them have shown efficacy in laboratory animals. However, the paucity of financial support has made it difficult to transfer effective candidates from the preclinical stage to clinical trials. Here, we summarize currently available MERS vaccine candidates and illustrate strategies for future development, with the aim of provoking government agencies and Big Pharma to invest more funds for developing efficacious and safe MERS vaccines.

KEYWORDS:

Animal models; Middle East respiratory syndrome; Middle East respiratory syndrome coronavirus; receptor-binding domain; spike protein; vaccines

PMID:
26414077
PMCID:
PMC4636333
DOI:
10.1517/14712598.2015.1092518
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center